- The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis2014 | First Faculty of Medicine
- Which walking capacity tests to use in multiple sclerosis? A RIMS multicenter study providing the basis for a core set2012 | Third Faculty of Medicine
- Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM2015 | First Faculty of Medicine
- Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5)2016 | First Faculty of Medicine
- Neuropsychological assessment of patients with early onset Friedreich's ataxia – Screening or comprehensive examination?2021 | Second Faculty of Medicine
- Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?2019 | First Faculty of Medicine
- Association between cognitive impairment and the disability in people with multiple sclerosisPublication without faculty affiliation
- Assessment set for evaluation of clinical outcomes in multiple sclerosis: psychometric properties2012 | Third Faculty of Medicine
- Improving our understanding of the most important items of the Multiple Sclerosis Walking Scale-12 indicating mobility dysfunction: Secondary results from a RIMS multicenter study2020 | Third Faculty of Medicine
- Neuropsychological assessment of patients with early onset Friedreich's ataxia2022 | Second Faculty of Medicine
- Responsiveness and clinically meaningful improvement, according to disability level, of five walking measures after rehabilitation in multiple sclerosis: A European multicenter study2014 | Third Faculty of Medicine
- Randomized comparison of functional electric stimulation in posturally corrected position and motor program activating therapy: treating foot drop in people with multiple sclerosis2020 | Third Faculty of Medicine, Faculty of Mathematics and Physics
- Is the impact of fatigue related to walking capacity and perceived ability in persons with multiple sclerosis? A multicenter study2018 | Third Faculty of Medicine
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension2018 | First Faculty of Medicine